Cefepime inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysis and murein hydrolases) while cell wall assembly is arrested.
Unipim-500 IM/IV Injection
Abdominal infections, Respiratory tract infections, Skin and skin structure infections, Urinary tract infections:
Adult: Mild to moderate infections: 1-2 g daily in 2 divided doses. Severe infections: Up to 4 g daily in 2 divided doses. Doses are given by deep IM inj or IV infusion over at least 30 min.
Child: Neonates: 30 mg/kg 12 hrly, may increase to 50 mg/kg for Pseudomonas infections; >30 days Mild to moderate infections: 100 mg/kg daily in 2 divided doses. Severe infections: Up to 150 mg/kg daily in 2 or 3 divided doses. Total dose should not exceed the recommended adult dosage.
Empiric therapy for febrile neutropenic patients:
Adult: Up to 6 g daily in 3 divided doses. Doses are given by deep IM inj or IV infusion over at least 30 min.